Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Cited by (1,000)

Items 201–300 of 1,000

1. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
   Chung, Katherine Minjee, Singh, Jaffarguriqbal, Lawres, Lauren, Dorans, Kimberly Judith, Garcia, Cathy, Burkhardt, Daniel B., Robbins, Rebecca, Bhutkar, Arjun, Cardone, Rebecca, Zhao, Xiaojian et al. · 2020 · Cell
2. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function
   Sara Donzelli, Giulia Fontemaggi, Francesco Fazi, Silvia Di Agostino, F Padula, Francesca Biagioni, Paola C. Muti, Sabrina Strano, Giovanni Blandino · 2011 · Cell Death and Differentiation
3. Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma
   Morton, Jennifer P., Karim, Saadia A., Graham, Kathryn, Timpson, Paul, Jamieson, Nigel, Athineos, Dimitris, Doyle, Brendan, McKay, Colin, Heung, Man–Yeung, Oien, Karin A. et al. · 2010 · Gastroenterology
4. Intravital microscopy: new insights into metastasis of tumors
   Evelyne Beerling, Laila Ritsma, Nienke Vrisekoop, Patrick W.B. Derksen, Jacco van Rheenen · 2011 · Journal of Cell Science
5. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
   Robert A. Jones, Tyler Robinson, Jeff C. Liu, Mariusz Shrestha, Véronique Voisin, YoungJun Ju, Philip E.D. Chung, Giovanna Pellecchia, Victoria L. Fell, Sooin Bae et al. · 2016 · Journal of Clinical Investigation
6. Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
   Adam Samuel Sperling, Veronica A. Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang, Andrew T. Nguyen, Peter Grant Miller, Marie Ellen McConkey, Vanessa A. Quevedo Barrios et al. · 2022 · Blood
7. Oncogenic MicroRNAs: Key Players in Malignant Transformation
   Tania Frixa, Sara Donzelli, Giovanni Blandino · 2015 · Cancers
8. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine
   Claudia Fiorini, Marco Cordani, Chiara Padroni, Giovanni Blandino, Silvia Di Agostino, Massimo Donadelli · 2014 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
9. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
   Neil T. Pfister, Vitalay Fomin, Kausik Regunath, Jeffrey Y. Zhou, Wen Zhou, Laxmi Silwal‐Pandit, William A. Freed-Pastor, Oleg Laptenko, Suat Peng Neo, Jill Bargonetti et al. · 2015 · Genes & Development
10. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations
    Carlos Caulı́n, Thao Nguyen, Gene A. Lang, Thea M. Goepfert, Bill Robert Brinkley, Wei‐Wen Cai, Guillermina Lozano, Dennis R. Roop · 2007 · Journal of Clinical Investigation
11. The UMD TP53 database and website: update and revisions
    Hamroun, Dalil, Kato, Shunsuke, Ishioka, Chikashi, Claustres, Mireille, Béroud, Christophe, Soussi, Thierry · 2006 · Human Mutation
12. High resolution melting for mutation scanning of TP53exons 5–8
    Michael Krypuy, Ahmed A. Ahmed, Dariush Etemadmoghadam, Sarah J. Hyland, Georgia Chenevix‐Trench, Anna DeFazio, Stephen B. Fox, James D. Brenton, David D.L. Bowtell, Alexander Dobrovic · 2007 · BMC Cancer
13. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma
    Zhao, S, Kurenbekova, L, Gao, Y, Roos, A, Creighton, C J, Rao, P, Hicks, J, Man, T-K, Lau, C, Brown, A M C et al. · 2015 · Oncogene
14. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis
    Xiaohua Su, Deepavali Chakravarti, Elsa Renee Flores · 2013 · Nature reviews. Cancer
15. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers
    Lawrence R. Dearth, Qian Hua, Ting Wang, Timothy E. Baroni, Jue Zeng, Stephanie W. Chen, Sun Young Yi, Rainer Karl Brachmann · 2006 · Carcinogenesis
16. Role of Autophagy in Breast Cancer
    Vassiliki Karantza, Eileen White · 2007 · Autophagy
17. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
    Thorsten Stiewe, Tali E. Haran · 2018 · Drug Resistance Updates
18. TP53 in bone and soft tissue sarcomas
    Elizabeth A. Thoenen, Amanda Curl, Tomoo Iwakuma · 2019 · Pharmacology & Therapeutics
19. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53
    Neil T. Pfister, Carol L. Prives · 2016 · Cold Spring Harbor Perspectives in Medicine
20. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)
    Boon Shing Tan, Kai Hung Tiong, Heng Lungh Choo, Felicia Fei‐Lei Chung, Ling‐Wei Hii, S H Tan, I KS Yap, Sarita Pani, N TW Khor, Shew Fung Wong et al. · 2015 · Cell Death and Disease
21. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors
    Barbara Seidler, Annegret Schmidt, Ulrich Mayr, Hassan Nakhai, Roland Michael Schmid, Günter Schneider, Dieter Saur · 2008 · Proceedings of the National Academy of Sciences
22. Extracellular vesicles and particles impact the systemic landscape of cancer
    Serena Lucotti, Candia M. Kenific, Haiying Zhang, David C. Lyden · 2022 · The EMBO Journal
23. Combined Mutation of <i>Apc, Kras</i> , and <i>Tgfbr2</i> Effectively Drives Metastasis of Intestinal Cancer
    Sakai, Eri, Nakayama, Mizuho, Oshima, Hiroko, Kouyama, Yuta, Niida, Atsushi, Fujii, Satoshi, Ochiai, Atsushi, Nakayama, Keiichi I., Mimori, Koshi, Suzuki, Yutaka et al. · 2018 · Cancer Research
24. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression
    Chang‐Il Hwang, Andrés Matoso, David C. Corney, Andrea Flesken‐Nikitin, Stefanie Körner, Wei Wang, Carla Boccaccio, Snorri S. Thorgeirsson, Paolo Maria Comoglio, Heiko Hermeking et al. · 2011 · Proceedings of the National Academy of Sciences
25. Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
    Milena Wiech, Maciej B. Olszewski, Zuzanna Tracz‐Gaszewska, Bartosz Wawrzynów, Maciej Żylicz, Maciej Żylicz · 2012 · PLoS ONE
26. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation
    Yongxing Wang, Young‐Ah Suh, Maren Y. Fuller, James G. Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás‐Cardama, James A. Bankson, Adel K. El‐Naggar, Guillermina Lozano · 2011 · Journal of Clinical Investigation
27. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
    Amanda R. Wasylishen, Guillermina Lozano · 2016 · Cold Spring Harbor Perspectives in Medicine
28. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo
    Avinashnarayan Venkatanarayan, Payal Raulji, William Norton, Deepavali Chakravarti, Cristian Coarfa, Xiaohua Su, Santosh K. Sandur, Marc S. Ramirez, Jaehuk Lee, Charles V. Kingsley et al. · 2014 · Nature
29. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression
    Tuo Hu, Surendra Kumar Shukla, Enza Vernucci, Chunbo He, Dezhen Wang, Ryan J. King, Kanupriya Jha, Kasturi Siddhanta, Nicholas J. Mullen, Kuldeep Singh Attri et al. · 2021 · Gastroenterology
30. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer
    Jan Grimm, David G. Kirsch, Stephen D. Windsor, Carla F. Bender Kim, Philip M. Santiago, Vasilis Ntziachristos, Tyler Jacks, Ralph Weissleder · 2005 · Proceedings of the National Academy of Sciences
31. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
    Pant, Vinod, Quintás-Cardama, Alfonso, Lozano, Guillermina · 2012 · Blood
32. Therapeutic options for the management of pancreatic cancer
    Maria L Rossi · 2014 · World Journal of Gastroenterology
33. Tumor suppressor p53 and its gain-of-function mutants in cancer
    Juan Liu, Cen Zhang, Zhaohui Feng · 2013 · Acta Biochimica et Biophysica Sinica
34. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth
    Nicola Rath, Jennifer P. Morton, Linda Julian, Lena Helbig, Shereen R. Kadir, Ewan James McGhee, Kurt I. Anderson, Gabriela Kalna, Margaret Mullin, Andreia V. Pinho et al. · 2016 · EMBO Molecular Medicine
35. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities
    Kollareddy, Madhusudhan, Dimitrova, Elizabeth, Vallabhaneni, Krishna C., Chan, Adriano, Le, Thuc, Chauhan, Krishna M., Carrero, Zunamys I., Ramakrishnan, Gopalakrishnan, Watabe, Kounosuke, Haupt, Ygal et al. · 2015 · Nature Communications
36. Control of cell migration: a tumour suppressor function for p53?
    Lauréline Roger, Gilles Gadéa, Pierre Roux · 2006 · Biology of the Cell
37. Biology of Osteogenic Sarcoma
    Lisa L. Wang · 2005 · The Cancer Journal
38. Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels
    David Novo, Nikki Heath, Louise E. Mitchell, Giuseppina Caligiuri, Amanda MacFarlane, Dide Reijmer, Laura Charlton, John R. P. Knight, Monika Calka, Ewan James McGhee et al. · 2018 · Nature Communications
39. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression
    Wenyu Wang, B Cheng, Lin Miao, Yide Mei, Mian Wu · 2013 · Cell Death and Disease
40. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications
    Rui Kamada, 侑 戸口, Takao Nomura, Toshiaki Imagawa, Kazuyasu Sakaguchi · 2015 · Biopolymers
41. Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR
    C. Cohen, Zhi-Li Zheng, R. Bray, Yang-Bing Zhao, L. Sherman, S. Rosenberg, R. Morgan · 2005 · Journal of Immunology
42. p53 tetramerization: at the center of the dominant-negative effect of mutant p53
    Jovanka Gencel‐Augusto, Guillermina Lozano · 2020 · Genes & Development
43. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression
    Haruna Takeda, Zhubo Wei, Hideto Koso, Alistair G. Rust, Christopher Chin Kuan Yew, Michael B. Mann, Jerrold Michael Ward, David J. Adams, Neal G. Copeland, Nancy A. Jenkins · 2015 · Nature Genetics
44. Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes
    Jonathan R. Hall, Zachary J. Messenger, Hann W. Tam, S. Phillips, Leslie Recio, Robert C. Smart · 2015 · Cell Death and Disease
45. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
    Sisi Chen, Qiang Wang, Hao Yu, Maegan L. Capitano, Sasidhar Vemula, Sarah C. Nabinger, Rui Gao, Chonghua Yao, Michihiro Kobayashi, Zhuangzhuang Geng et al. · 2019 · Nature Communications
46. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer
    Tobiloba E. Oni, Giulia Biffi, Lindsey A. Baker, Hao Yuan, Claudia Tonelli, Tim D.D. Somerville, Astrid Deschênes, Pascal Belleau, Chang‐Il Hwang, Francisco J. Sánchez Rivera et al. · 2020 · The Journal of Experimental Medicine
47. TAp63 Is a Master Transcriptional Regulator of Lipid and Glucose Metabolism
    Xiaohua Su, Young Jin Gi, Deepavali Chakravarti, Io Long Chan, Aijun Zhang, Xuefeng Xia, Kenneth Yee Tsai, Elsa Renee Flores · 2012 · Cell Metabolism
48. Emerging Roles of p53 Family Members in Glucose Metabolism
    Yoko Itahana, Koji Itahana · 2018 · International Journal of Molecular Sciences
49. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles
    Christina Matheny, Maren E. Speck, Patrick R. Cushing, Yunpeng Zhou, Takeshi Corpora, Michael C. Regan, Miki N. Newman, Liya Roudaia, Caroline L. Speck, Ting-Lei Gu et al. · 2007 · The EMBO Journal
50. p53 and the Carcinogenicity of Chronic Inflammation
    Andrei V. Gudkov, Elena A. Komarova · 2016 · Cold Spring Harbor Perspectives in Medicine
51. Multiple Stress Signals Activate Mutant p53 In Vivo
    Young‐Ah Suh, Sean M. Post, Ana C. Elizondo-Fraire, Daniela R. Macció, James G. Jackson, Adel K. El‐Naggar, Carolyn Van Pelt, Tamara Terzian, Guillermina Lozano · 2011 · Cancer Research
52. Cell of origin influences pancreatic cancer subtype
    Flowers, Brittany M., Xu, Hang, Mulligan, Abigail S., Hanson, Kathryn J., Seoane, Jose A., Vogel, Hannes, Curtis, Christina, Wood, Laura D., Attardi, Laura D. · 2021 · Cancer Discovery
53. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility
    Mingxuan Xia, Hartmut Land · 2007 · Nature Structural & Molecular Biology
54. The Function of the Mutant p53-R175H in Cancer
    Yen-Ting Chiang, Yi‐Chung Chien, Yuheng Lin, Hui-Hsuan Wu, Dung‐Fang Lee, Yung‐Luen Yu · 2021 · Cancers
55. A P53-Phosphoinositide Signalosome Regulates Nuclear AKT Activation
    Chen, Mo, Choi, Suyong, Wen, Tianmu, Chen, Changliang, Thapa, Narendra, Lee, Jeong Hyo, Cryns, Vincent L., Anderson, Richard A. · 2022 · Nature Cell Biology
56. Somatic <i>TP53</i> Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity
    Libè, Rossella, Groussin, Lionel, Tissier, Frédérique, Elie, Caroline, René-Corail, Fernande, Fratticci, Amato, Jullian, Eric, Beck-Peccoz, Paolo, Bertagna, Xavier, Gicquel, Christine et al. · 2007 · Clinical Cancer Research
57. Dietary downregulation of mutant p53 levels via glucose restriction
    Olga Catalina Rodriguez, Sujatra Choudhury, Vamsi Krishna Kolukula, Eveline E. Vietsch, Jason Catania, Anju Preet, Katherine Reynoso, Jill Bargonetti, Anton Wellstein, Chris Albanese et al. · 2012 · Cell Cycle
58. Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression
    Ikuno Uehara, Nobuyuki Tanaka · 2018 · Cancers
59. p53 downstream target genes and tumor suppression: a classical view in evolution
    Laura M. Rozan, Wafik S. El‐Deiry · 2006 · Cell Death and Differentiation
60. Regulators of Oncogenic Mutant TP53 Gain of Function
    Satomi Yamamoto, Tomoo Iwakuma · 2018 · Cancers
61. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5
    Vogiatzi, Fotini, Brandt, Dominique T., Schneikert, Jean, Fuchs, Jeannette, Grikscheit, Katharina, Wanzel, Michael, Pavlakis, Evangelos, Charles, Joël P., Timofeev, Oleg, Nist, Andrea et al. · 2016 · Proceedings of the National Academy of Sciences
62. Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma
    Patrizia Cammareri, Aidan Rose, David F. Vincent, Jun Wang, A. Nagano, Silvana Libertini, Rachel A. Ridgway, Dimitris Athineos, Philip John Coates, Angela T. McHugh et al. · 2016 · Nature Communications
63. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations
    Therese Seidlitz, Yi‐Ting Chen, Heike Uhlemann, Sebastian Schölch, Susan Kochall, Sebastian R. Merker, Anna Klimová, Alexander Hennig, Christine Schweitzer, Kristin Pape et al. · 2019 · Gastroenterology
64. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
    Ori Hassin, Nishanth Belugali Nataraj, Michal Shreberk‐Shaked, Yael Aylon, Rona D. Yaeger, Giulia Fontemaggi, Saptaparna Mukherjee, Martino Maddalena, Adi Seligman, Ortal Iancu et al. · 2022 · Nature Communications
65. Mutant p53 Induces the GEF-H1 Oncogene, a Guanine Nucleotide Exchange Factor-H1 for RhoA, Resulting in Accelerated Cell Proliferation in Tumor Cells
    Shinji Mizuarai, Kazunori Yamanaka, Hidehito Kotani · 2006 · Cancer Research
66. VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma
    Cláudio R. Santos, Maria Socorro Rodriguez-Pinilla, Francisco M. De La Vega, José Luis Rodríguez‐­Peralto, Sandra Blanco, Ana Sevilla, Alberto Valbuena, Teresa Hernández, André J. van Wijnen, Fengzhi Li et al. · 2006 · Molecular Cancer Research
67. Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α
    Subhasree Basu, Keerthana Gnanapradeepan, Thibaut Barnoud, Che-Pei Kung, Michele Tavecchio, Jeremy Scott, Andrea K. Watters, Qing Chen, Andrew V. Kossenkov, Maureen E. Murphy · 2018 · Genes & Development
68. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
    Tongsen Zheng, Jiabei Wang, Yuhan Zhao, Cen Zhang, Meihua Lin, Xiaowen Wang, Haiyang Yu, Lianxin Liu, Zhaohui Feng, Wenwei Hu · 2013 · Nature Communications
69. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
    MichaelP Kim, Yun Zhang, Guillermina Lozano · 2015 · Frontiers in Oncology
70. p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner
    Yoseph Addadi, Neta Ben-Chaim Moskovits, Dorit Granot, Guillermina Lozano, Yaron Carmi, Ron N. Apte, Michal Neeman, Moshe Oren · 2010 · Cancer Research
71. Aberrant hnRNP K expression: All roads lead to cancer
    Miguel Gallardo, Marisa J.L. Aitken, Xiaorui Zhang, Peter C. Hu, Carlos Bueso-Ramos, Sean M. Post · 2016 · Cell Cycle
72. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
    N Stojanovic, Zonera Hassan, Matthias Wirth, Patrick Wenzel, Mandy Beyer, C Schäfer, P Brand, Alexander Kroemer, Roland H. Stauber, Roland Michael Schmid et al. · 2016 · Oncogene
73. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism
    Matilda Eriksson, Gorbatchev Ambroise, Amanda Tomie Ouchida, André Lima Queiroz, Dominique H. Smith, Alfredo Giménez-Cassina, Marcin Iwanicki, Patricia A. J. Muller, Erik Norberg, Helin Vakifahmetoglu-Norberg · 2017 · Molecular and Cellular Biology
74. Hsp70- and Hsp90-Mediated Regulation of the Conformation of p53 DNA Binding Domain and p53 Cancer Variants
    Marta Boysen, Roman Kityk, Matthias P. Mayer · 2019 · Molecular Cell
75. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
    Ramona Schulz‐Heddergott, Ute Martha Moll · 2018 · Cancers
76. An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells
    Mohammad B. Uddin, Kartik R. Roy, Salman B. Hosain, Sachin Khiste, Ronald A. Hill, Seetharama D. S. Jois, Yunfeng Zhao, Alan J. Tackett, Yu Liu · 2018 · Biochemical Pharmacology
77. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells
    Lauréline Roger, Laurent Jullien, Véronique Gire, Pierre Roux · 2010 · Journal of Cell Science
78. Overexpression of Interleukin-1β in the Murine Pancreas Results in Chronic Pancreatitis
    Frédéric Marrache, Shui Ping Tu, Govind Bhagat, Swaroop Pendyala, Christoph H. Österreicher, Shanisha A. K. Gordon, Vigneshwaran Ramanathan, Melitta Penz-Österreicher, Kelly S. Betz, Zhigang Song et al. · 2008 · Gastroenterology
79. Differential regulation of the REGγ–proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells
    Amjad Ali, Zhuo Wang, Junjiang Fu, Lei Ji, Jiang Liu, Lei Li, Hui Wang, Jiwu Chen, Carlos Caulı́n, Jeffrey N. Myers et al. · 2013 · Nature Communications
80. The paradigm of mutant p53-expressing cancer stem cells and drug resistance
    Yoav Shetzer, Hilla Solomon, Gabriela Koifman, Alina Molchadsky, Stav Horesh, Varda Rotter · 2014 · Carcinogenesis
81. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways
    Serge J. Smeets, Marlon van der Plas, Tieneke B.M. Schaaij‐Visser, Eva A.M. van Veen, Johan van Meerloo, Boudewijn J.M. Braakhuis, Renske D.M. Steenbergen, Ruud H. Brakenhoff · 2010 · International Journal of Cancer
82. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high ROS levels
    Eyal Kalo, Ira Kogan-Sakin, Hilla Solomon, Elad Bar Natan, Moshe Shay, Yoav Shetzer, Elya Dekel, Naomi Goldfinger, Yossi Buganim, Perry Stambolsky et al. · 2012 · Journal of Cell Science
83. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
    Evguenia M. Alexandrova, Safia A Mirza, Sulan Xu, Ramona Schulz‐Heddergott, Natalia D. Marchenko, Ute Martha Moll · 2017 · Cell Death and Disease
84. A genetic mouse model for metastatic lung cancer with gender differences in survival
    Siyuan Zheng, Adel K. El‐Naggar, E S Kim, Jonathan M. Kurie, Guillermina Lozano · 2007 · Oncogene
85. Molecular and Cellular Biology of Rhabdomyosarcoma
    Carla De Giovanni, Lorena Landuzzi, Giordano Nicoletti, Pier‐Luigi Lollini, Patrizia Nanni · 2009 · Future Oncology
86. A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress
    Dun Li, Alisha R. Yallowitz, Lukasz S. Ozog, N D Marchenko · 2014 · Cell Death and Disease
87. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer
    Volker Fendrich, NM Chen, M. Neef, J. Waldmann, Malte Buchholz, Georg Feldmann, E. P. Slater, Anirban Maitra, Detlef Klaus Bartsch · 2009 · Gut
88. Aberrant phase separation and cancer
    Kenzui Taniue, Nobuyoshi Akimitsu · 2021 · FEBS Journal
89. High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray
    Dong Yin, Seishi Ogawa, Norihiko Kawamata, Patrizia Tunici, Gaetano Finocchiaro, Marica Eoli, Christian Rückert, Thien Phuoc Huynh, Gentao Liu, Motohiro Kato et al. · 2009 · Molecular Cancer Research
90. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53
    Shunbin Xiong, Huolin Tu, Madhu Kollareddy, Vinod Pant, Qin Li, Yun Zhang, James G. Jackson, Young‐Ah Suh, Ana C. Elizondo-Fraire, Peirong Yang et al. · 2014 · Proceedings of the National Academy of Sciences
91. p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication
    Constance Yeo, Irina Alexander, Zhaoru Lin, Shuhui Lim, Obed Akwasi Aning, Ramesh Kumar, Kanda Sangthongpitag, Vishal V. Pendharkar, Vincent H.B. Ho, Chit Fang Cheok · 2016 · Cell Reports
92. Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo
    Ming Kei Lee, Wei Wei Teoh, Beng Hooi Phang, Wei Tong, Zhao Qi Wang, Kanaga Sabapathy · 2012 · Cancer Cell
93. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
    Jie Xu, J Wang, Yiqun Hu, J Qian, B Xu, H Chen, W Zou, J-Y Fang · 2014 · Cell Death and Disease
94. Degradation of mutant p53H175 protein by Zn(II) through autophagy
    Alessia Garufi, D. Pucci, Valerio D’Orazi, Mara Cirone, Gianluca Bossi, Maria Laura Avantaggiati, Gabriella D’Orazi · 2014 · Cell Death and Disease
95. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
    Hui Li, Jinglin Zhang, JOANNA H.M. TONG, Anthony W.H. Chan, Jun Qing Yu, Wei Kang, Ka Fai To · 2019 · International Journal of Molecular Sciences
96. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
    Bin Song, Ping Yang, Shuyu Zhang · 2024 · 癌症：英文版
97. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
    Li, Yunqing, Guessous, Fadila, Kwon, Sherwin, Kumar, Manish, Ibidapo, Opeyemi, Fuller, Lauren, Johnson, Elizabeth, Lal, Bachchu, Hussaini, Isa, Bao, Yongde et al. · 2008 · Cancer Research
98. High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease
    Yali Zhai, RONG TSUN WU, Rork D. Kuick, Michael S. Sessine, Stephanie Schulman, Megan Green, Eric R. Fearon, Kathleen R. Cho · 2017 · The Journal of Pathology
99. Do Mutations Turn p53 into an Oncogene?
    Consuelo Pitolli, Ying Wang, Mara Mancini, Yufang Shi, Gerry Melino, Ivano Amelio · 2019 · International Journal of Molecular Sciences
100. Mouse Models of p53 Functions
     Guillermina Lozano · 2009 · Cold Spring Harbor Perspectives in Biology